Zacks Investment Research covered Aradigm Corporation (NASDAQ:ARDM), bumping up its stock price target to $7.25 today
- Updated: September 26, 2016
Aradigm Corporation (NASDAQ:ARDM) had its price target increased to $7.25 by Zacks Investment Research in an issued report announced 9/26/2016. The latest target price indicates a potential upside of 0.12% from the company's previous stock price.
Only yesterday Aradigm Corporation (NASDAQ:ARDM) traded 2.62% higher at $6.50. Aradigm Corporation’s 50-day moving average is $4.77 and its 200-day moving average is $4.52. With the last close up 47.57% from the 200-day moving average, compared to the S&P 500 Index which has decreased -0.01% over the same time. Trading volume was up over the average, with 65,200 shares of ARDM changing hands over the typical 8,894
Recent Performance Chart
Aradigm Corporation has a one year low of $2.60 and a one year high of $7.40 Aradigm Corporation’s market capitalization is presently $0.
Brief Synopsis On Aradigm Corporation (NASDAQ:ARDM)
Aradigm Corporation is a pharmaceutical company focused on the development and commercialization of products for the treatment and prevention of severe respiratory diseases. The Company's lead product candidate is Pulmaquin inhaled ciprofloxacin, which is in Phase III clinical trials. It offers AERx pulmonary drug delivery platform and other technologies. Its partnered programs under development include Inhaled Ciprofloxacin. It is also engaged in developing Smoking Cessation Therapy (ARD-1600 Inhaled Nicotine). Its lead development candidates are its formulations of the potent antibiotic ciprofloxacin (Pulmaquin (ARD-3150) and Lipoquin (ARD-3100)) that are delivered by inhalation for the management of infections associated with the severe respiratory diseases, such as cystic fibrosis (CF) and non-cystic fibrosis bronchiectasis (BE). Pulmaquin uses slow release liposomal formulation (Lipoquin) mixed with a small amount of ciprofloxacin dissolved in an aqueous medium.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.